Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
77 hedge funds and large institutions have $26.9M invested in Melinta Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 19 reducing their positions, and 28 closing their positions.
58% more call options, than puts
Call options by funds: $19K | Put options by funds: $12K
32% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 19
15% less funds holding
Funds holding: 91 → 77 (-14)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 28
82% less capital invested
Capital invested by funds: $149M → $26.9M (-$123M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$2.45M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.72M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
+$1.26M |
| 4 |
Two Sigma Investments
New York
|
+$656K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$456K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$7.74M |
| 2 |
DM
Deerfield Management
New York
|
-$5.06M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.71M |
| 4 |
First Manhattan
New York
|
-$1.6M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.22M |
MLNT Hedge Fund Activity: Q4 2018 in Review
77 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q4 2018, worth a combined $26.9M — down 82% from $149M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of MLNT and 14 opened new positions — a net loss of 14 holders — while 19 trimmed existing stakes and 25 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.45M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $7.74M sold.
- 77 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q4 2018, down from 91 in Q3 2018.
- Funds reported $26.9M of Melinta Therapeutics, Inc. Common Stock stock for Q4 2018, down 82% quarter-over-quarter.
- 14 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q4 2018 and 28 closed out, a net change of -14 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $2.45M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q4 2018 was Stonepine Capital Management, an estimated $7.74M sold.
Based on aggregated 13F filings for Q4 2018.